DexCom, Inc. (NASDAQ:DXCM) Short Interest Update

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,420,000 shares, a decline of 7.7% from the November 15th total of 9,120,000 shares. Based on an average trading volume of 4,170,000 shares, the short-interest ratio is currently 2.0 days.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.30% of the stock is owned by company insiders.

Institutional Trading of DexCom

Hedge funds have recently bought and sold shares of the company. Capital Insight Partners LLC lifted its stake in shares of DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company's stock worth $418,000 after purchasing an additional 90 shares during the period. Clear Creek Financial Management LLC boosted its stake in DexCom by 4.2% in the 2nd quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company's stock worth $336,000 after buying an additional 120 shares during the last quarter. SeaCrest Wealth Management LLC grew its holdings in DexCom by 3.6% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company's stock valued at $501,000 after buying an additional 152 shares during the period. B. Riley Wealth Advisors Inc. increased its stake in shares of DexCom by 4.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company's stock valued at $445,000 after acquiring an additional 162 shares during the last quarter. Finally, Apollon Wealth Management LLC increased its stake in shares of DexCom by 0.7% during the 2nd quarter. Apollon Wealth Management LLC now owns 22,143 shares of the medical device company's stock valued at $2,511,000 after acquiring an additional 163 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of recent analyst reports. Sanford C. Bernstein upped their price objective on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Royal Bank of Canada reduced their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. lifted their price target on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $98.00.

DexCom Trading Down 1.0 %

NASDAQ:DXCM traded down $0.78 on Monday, reaching $76.41. The stock had a trading volume of 4,013,183 shares, compared to its average volume of 3,884,968. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market cap of $29.85 billion, a price-to-earnings ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12. The firm's fifty day moving average is $73.76 and its two-hundred day moving average is $84.04. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.